Amgen stock: buy or sell?
Updated on:
September 20th, 2019
5
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology\u002Fhematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.
Should I buy Amgen stock?
Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading plan that matches with your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.None of our preferred buy setups matches with Amgen stock situation right now, hence this is not a suitable entry point.
| Buy setup | Elegible |
|---|---|
| New all-time high | No |
| New 52 week high | No |
| Price crossing up 200d MA | No |
| 100d MA crossing up 200d MA | No |
Is Amgen stock a buy?
Financial institutions and banks post stock ratings everyday.
At Stocks2.com, we collected 15 ratings published for AMGN stock in the last 30 days.| Date | Analyst / Broker | Previous rating | Current rating |
| 2019-9-5 | Cantor Fitzgerald | n/a | Neutral |
| 2019-8-30 | William Blair | n/a | Hold |
| 2019-8-29 | JPMorgan Chase & Co. | n/a | Neutral |
| 2019-8-27 | Wells Fargo & Co | n/a | Market Perform |
| 2019-8-27 | Royal Bank of Canada | n/a | Sector Perform |
| 2019-8-27 | JPMorgan Chase & Co. | n/a | Hold |
| 2019-8-27 | BMO Capital Markets | n/a | Outperform |
| 2019-8-21 | Royal Bank of Canada | n/a | Sector Perform |
| 2019-8-19 | Mizuho | Buy | Neutral |
| 2019-8-16 | Credit Suisse Group | n/a | Outperform |
| 2019-8-13 | Oppenheimer | n/a | Outperform |
| 2019-8-12 | Wells Fargo & Co | Market Perform | Positive |
| 2019-7-15 | Morgan Stanley | n/a | Overweight |
| 2019-7-1 | Mizuho | n/a | Buy |
| 2019-6-24 | Mizuho | n/a | Buy |
Amgen stock analysis
Daily outlook
Amgen closed today at $196.94 and grew a tiny 0.66%.
Amgen closed today at $196.94 and grew a tiny 0.66%. Since last August 8th when AMGN stock price broke up the SMA200d line, it gained $14.69 (8.06%). On Aug/9, SMA50d and SMA100d crossed up triggering a rise of 7.07%. On August 30th, AMGN hit new all time highs, pushing higher previous ATH of $210.41 recorded on August 13th. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
Weekly outlook
After sliding a scary -6.27% in a week last week, Amgen closed this week at $196.94 and inched a slightly fine 0.75%. Late July AMGN skyrocketed an extraordinary 6.34% in just one week.
Amgen stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, AMGN might consolidate in a flat-base, waiting to break out over or down under . Not so far away is the last price record Amgen marked late August. Late July AMGN price bounced up over the SMA of 40 weeks that acted as support stopping new slides.
Amgen stock price history
Amgen stock went public on June 17th, 1983 with a price of $0.291. Since then, AMGN stock surged a 67,810.30%, with an average of 1,883.60% per year. If you had invested right after AMGN's IPO a $1,000 in Amgen stock in 1983, it would worth $678,103.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Amgen stock historical price chart
AMGN stock reached all-time highs on August/30 with a price of $210.97.
Amgen stock price target is $213.70
How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' AMGN stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 13 price targets for AMGN stock:| Date | Analyst / Broker | Action | Previous target | Current target | Diff |
| 2019-9-5 | Cantor Fitzgerald | Reiterates | $221.00 | $230.00 | 4.1% |
| 2019-8-29 | JPMorgan Chase & Co. | Raises Target | $191.00 | $198.00 | 3.7% |
| 2019-8-27 | Wells Fargo & Co | Reiterates | $202.00 | $220.00 | 8.9% |
| 2019-8-27 | Royal Bank of Canada | Raises Target | $192.00 | $206.00 | 7.3% |
| 2019-8-27 | BMO Capital Markets | Raises Target | $230.00 | $240.00 | 4.3% |
| 2019-8-21 | Royal Bank of Canada | Raises Target | n/a | $192.00 | - |
| 2019-8-19 | Mizuho | Downgrades | $208.00 | $212.00 | 1.9% |
| 2019-8-16 | Credit Suisse Group | Reiterates | $202.00 | $225.00 | 11.4% |
| 2019-8-13 | Oppenheimer | Raises Target | $210.00 | $230.00 | 9.5% |
| 2019-8-12 | Wells Fargo & Co | Reiterates | $197.00 | $202.00 | 2.5% |
| 2019-7-15 | Morgan Stanley | Lowers Target | $211.00 | $207.00 | -1.9% |
| 2019-7-1 | Mizuho | Reiterates | n/a | $208.00 | - |
| 2019-6-24 | Mizuho | Reiterates | n/a | $208.00 | - |
| (in average) | $206.40 | $213.70 | 4.0% |
Financials and fundamental analysis
Earnings date and Earnings per Share
Since April, when Amgen presented its last earnings report, it . As soon as we get its posted EPS from the earnings report, we will update this report.| Quarter | Reporting date | Estimated EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| 2017-Q2 | - | n/a | 2.91 | n/a |
| 2017-Q3 | 2017-10-25 | 3.11 | 3.27 | 5.1% |
| 2017-Q4 | 2018-02-01 | 3.03 | 2.89 | -4.6% |
| 2018-Q1 | 2018-04-24 | 3.23 | 3.47 | 7.4% |
| 2018-Q2 | 2018-07-26 | 3.52 | 3.83 | 8.8% |
| 2018-Q3 | 2018-10-30 | 3.42 | 3.69 | 7.9% |
| 2018-Q4 | 2019-01-29 | 3.26 | 3.42 | 4.9% |
| 2019-Q1 | 2019-04-22 | 3.48 | n/a | n/a |
| 2019-Q2 | - | n/a | n/a | n/a |
| 2019-Q3 | - | n/a | n/a | n/a |
Annual financial results
Compared to 2017, last anual sales report draw a beatiful growth of 3.93% to $23,747.00 M USD. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) boosted a 26.69% to 35.35%. Amgen presents anual results in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Amgen TTM sales up to March 2019 were $23,750.00 and income $8,075.00 M USD. If we compare this TTM figures with the last reported annuality, we can esteem Amgen business evolution since December 2018: Annual revenues up to March, compared to lastest yearly report, remained steady a tight 0.01%. In the same way, profit margin (net income/sales) decreased at 35.35%.| Year | Sales | YoY | Income/(margin) | YoY |
|---|---|---|---|---|
| 2013 | $18,670 M | - | $5,080 M27.2% | - |
| 2014 | $20,063 M | 7.46% | $5,158 M25.7% | 1.54% |
| 2015 | $21,662 M | 7.97% | $6,939 M32.0% | 34.53% |
| 2016 | $22,991 M | 6.14% | $7,722 M33.6% | 11.28% |
| 2017 | $22,849 M | -0.62% | $1,979 M8.7% | -74.37% |
| 2018 | $23,747 M | 3.93% | $8,394 M35.3% | 324.15% |
| TTM | $23,750 M | 0.01% | $8,075 M34.0% | -3.80% |
Quarterly financial results
Amgen reported $5,557.00 million in sales for 2019-Q1, a -10.80% less compared to previous quarter. Reported quarter earnings marked $1,992.00 M with a profit margin of 35.85%. Profit margin inched a 4.90% compared to previous quarter when profit margin was 30.95%. When comparing revenues to same quarter last year, Amgen sales marked a neutral movement and stayed steady a 0.05%.| Quarter | Sales1 | QoQ2 | Income1/(margin) | QoQ2 |
|---|---|---|---|---|
| 2017-Q2 | $5,780 M | - | $2,150 M37.2% | - |
| 2017-Q3 | $5,780 M | 0.00% | $2,020 M34.9% | -6.05% |
| 2017-Q4 | $5,802 M | 0.38% | $-4,264 M-73.5% | -311.09% |
| 2018-Q1 | $5,554 M | -4.27% | $2,311 M41.6% | -154.20% |
| 2018-Q2 | $6,059 M | 9.09% | $2,296 M37.9% | -0.65% |
| 2018-Q3 | $5,904 M | -2.56% | $1,859 M31.5% | -19.03% |
| 2018-Q4 | $6,230 M | 5.52% | $1,928 M30.9% | 3.71% |
| 2019-Q1 | $5,557 M | -10.80% | $1,992 M35.8% | 3.32% |
Amgen ownership
When you are planning to invest in a stock, it's worth to check its ownership structure.Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Amgen, 0.21% of all outstanding shares are owned by its staff.
Bearish positions for AMGN stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related stocks:
| AMGN | ABBV | ALXN | BIIB | BMY | |
|---|---|---|---|---|---|
| Market cap | $118.1 B | $106.1 B | $23.7 B | $43.5 B | $82.1 B |
| Total shares | 599.7 M | 1,480.0 M | 224.2 M | 184.5 M | 1,640.0 M |
| Float shares | 598.3 M | 1,480.0 M | 223.6 M | 184.0 M | 1,630.0 M |
| - Institutional holdings (%) | 81.9% | 71.9% | 96.8% | 93.4% | 75.0% |
| - Insider holdings (%) | 0.2% | 0.1% | 0.3% | 0.5% | 0.1% |
| Shares in short selling | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Amgen summary
| Friday, September 20th, 2019 | |
|---|---|
| Open | $196.00 |
| Close | $196.94 |
| Day range | $195.75 - $199.32 |
| Previous close | $195.65 |
| Session gain | 0.66% |
| Average true range | $3.81 |
| 50d mov avg | $192.19 |
| 100d mov avg | $183.57 |
| 200d mov avg | $185.01 |
| Daily pattern | lt03a |
| Weekly pattern | lt06a |
Amgen performance
To measure stock performance is always good to benchmark with competitors or related stocks. We compared Amgen against AbbVie, Alexion Pharmaceuticals, Biogen, Bristol-Myers Squibb, Celgene, Gilead Sciences, GlaxoSmithKline, and Pfizer in the following table:| Stock | 3m | 6m | 12m |
|---|---|---|---|
| AMGNAmgen | 6.00% | 7.15% | -1.03% |
| ABBVAbbVie | -7.64% | -7.56% | -18.24% |
| ALXNAlexion Pharmaceu... | -20.18% | -18.85% | -13.38% |
| BIIBBiogen | -1.45% | 8.73% | -31.79% |
| BMYBristol-Myers Squ... | 2.37% | 5.81% | -16.97% |
| CELGCelgene | 0.04% | 12.25% | 12.80% |
| GILDGilead Sciences | -4.04% | 5.40% | -9.37% |
| GSKGlaxoSmithKline | 4.57% | 3.33% | 8.61% |
| JNJ | -7.74% | -3.60% | -6.42% |
| PFEPfizer | -15.62% | -11.17% | -14.22% |
Amgen competitors
We chose a few stocks to conform a list of Amgen competitors to check if you are interested in investing in AMGN:- AbbVie (ABBV)
- Alexion Pharmaceuticals (ALXN)
- Biogen (BIIB)
- Bristol-Myers Squibb (BMY)
- Celgene (CELG)
- Gilead Sciences (GILD)
- GlaxoSmithKline (GSK)
- (JNJ)
- Pfizer (PFE)
Latest Amgen stock news
- Seeking AlphaMirati's Stock Gaps Higher On Amgen's Data, Opens Up Massive OpportunityJune 6, 2019
- Seeking AlphaAmgen Breaches Hurdle For Decades Of Research To Bring A New Drug To RealityJune 6, 2019
- InvestorPlaceAmgen Earnings: AMGN Stock Dips Slightly Despite Q1 EPS, Sales BeatApril 30, 2019
- Seeking AlphaAmgen Evenity Approval Just Makes It A HoldApril 18, 2019
- InvestorPlace3 Big Stock Charts for Thursday: Citrix Systems, Goldman Sachs Group and AmgenApril 18, 2019